Cancer Patients Need Good Care as Well as Technology

The cost of treating cancer with the latest drugs and technologies rises every day. Even developed countries express concern about affordability. We also debate whether these treatments extend survival in proportion to their high prices. Yet developed countries devote far less effort to improving patient care than to developing drugs and technology, although good supportive care can contribute as much as cancer drugs to survival and quality of life. We may be seriously overlooking something…
The Patient Waiting with Hope—or Hopelessness—for a Chance at Cancer Treatment
Setting aside the difficulties of cancer medicine in countries with advanced healthcare, including ours, in Nigeria, Malaysia, India and many other low- and middle-income countries, hundreds often queue in streets to see a cancer doctor. Chemotherapy predominates there, while radiotherapy and surgery are less available. In fact, %90 of people in low-income countries lack access even to basic radiotherapy .
Could Technology-Focused Cancer Care Do More Harm Than Good in Low- and Middle-Income Countries?
For the past 15 years, more than a dozen clinical research groups from 40 countries have studied cancer policies. Their findings show that everyone involved in oncology—researchers, doctors, policymakers and patient care groups—should focus on education and staffing to guarantee appropriate care at the right time for every patient.
A Growing Problem
New cancer diagnoses increase annually. Ten years ago, 12.7 million people worldwide lived with cancer, with an economic impact of approximately 290 billion dollars. By 2030, 21.7 million people are expected to be affected at a projected cost of 458 billion dollars; this reflects population aging and growth and lifestyle changes. But these figures vary dramatically between countries.
EUROCARE-5 shows substantial differences in cancer mortality and morbidity even within Europe. For example, in 2014, breast cancer survival differed by % 14.5 between Denmark, among the best cancer care providers, and Lithuania, among the worst. Rectal cancer survival varied between countries by as much as % 32.
Mortality rateis the annual rate of new deaths per 1000 people, also known as the crude death rate.
Morbidity rateis the ratio of people developing disease in a particular population and period to the population remaining healthy. It is also called the mortality rate. The word mortality is also used to mean the state of illness.
Asia likewise shows major differences: for breast or colorectal cancer , deaths within 1 year of diagnosis were, in research from 2012, %12 in Malaysia versus %45 in Myanmar. Meanwhile, 1/4 of patients in Thailand and 2/3 in Vietnam faced serious financial problems from treatment costs.
Hospitals in low-income countries lack basic infrastructure and personnel for cancer care. Mumbai’s Tata Cancer Center, India’s oldest and largest cancer treatment and research center, sees approximately 40.000 patients yearly with 164 senior faculty members. At MD Anderson, a leading American cancer center, annual patient numbers are 33.000, but senior faculty numbers are 11 times greater (1.834).
In sub-Saharan Africa, only 16 countries have access to basic pathology services. Cancer diagnosis requires equipment and trained staff. Africa averages one pathologist per 2.3 million people; high-income countries generally have one per 15.000 to 20.000.
Another problem is late-stage diagnosis. Five-year breast cancer survival in Tunisia is only% 68.4, compared with over %85 in countries with advanced healthcare, including ours. One reason is potential stigma against women with cancer in many low- and middle-income countries. Many need their husbands’ permission to seek care and fear diagnosis may lead to divorce.
Lack of education and awareness, financial hardship and unavailable treatment are key barriers to early diagnosis. Against this background, it is concerning that many low- and middle-income countries allocate cancer budgets to technology despite their existing shortcomings.
Consider the Cost
The past decade saw an explosion of targeted and immunotherapy drugs. Surgical and robotic technologies also multiplied, while techniques such as tomotherapy and proton therapy expand annually.
Many emerging economies are investing in these high-tech interventions despite lacking high-income countries’ purchasing and negotiating power or systems to assess cost-effectiveness.
A striking example among new radiotherapy technologies is proton therapy. Despite no demonstrated superiority over conventional radiotherapy for many cancers and much greater cost, at least 18 machines are planned in Brazil, Russia, India, China and South Africa. Each costs around 140 million dollars. These countries have approximately a % 60 shortfall in basic radiotherapy equipment and personnel, let alone infrastructure to operate proton therapy, whose cost-effectiveness is unproven.
Cancer surgery is another issue. Fewer than % 5 of patients in the lowest-income countries can access safe, affordable and timely cancer surgery; the figure in middle-income countries is % 22. Yet these same countries spend hundreds of millions annually on immunotherapy drugs.
Nevertheless, every advance in cancer medicine is valuable because it may save millions of lives. Immunotherapies, targeted cancer drugs, CAR-T and crispr New cancer treatments of this kind are costly because they embody vast knowledge and advanced technology. For the first time in cancer’s thousands-year history, these treatments make us think we can first turn cancer into a manageable disease and then a fully treatable one. (Cancer cannot be treated with plant extracts , but only with products specific to its complex biology, as scientific pioneers have long understood, and most cancer-treatment efforts have turned toward genetic technologies. Like other new products, these will become more accessible over time, for example after patents expire and biosimilars are produced. But excitement must not distract from the main focus: using available resources equitably and wisely and training personnel for good healthcare may contribute more to survival and quality of life than new drugs and technologies we struggle to access.
In short, developing countries underuse life-saving measures such as early detection through cancer screening tests, basic surgery and radiotherapy, while overusing expensive interventions that do not meaningfully benefit patients. Insufficient attention to care quality is a problem in developed as well as resource-limited countries. Our rapid, low-cost solutions are:
- Training healthcare staff for better care promises improved outcomes at much lower cost than developing a new drug.
- Oncology teams need enough specialized professionals, such as oncology nurses, palliative care specialists and complementary medicine specialists,
- Emphasize patient and family education throughout treatment,
- Provide social and psychological support alongside treatment,
- Oncological rehabilitation and palliative care should be routine components of cancer treatment,
- Smoking cessation support should be available. We emphasize this often, but the figures clarify its importance: reducing smoking prevalence in Europe by just %5 is projected to contribute 10 billion euros annually by preventing premature cancer deaths and treatment costs.
- Although most cancers occur after the 50s, health policies should firmly promote awareness that cancer-protective habits must begin in childhood.
We conclude with the words of this inspiring Nature article’s author, Prof. Dr. Richard Sullivan: “In cancer, technologies are ‘only’ tools. Sociopolitical and economic systems matter for good outcomes.”
Sources
Cancer patients need better care, not just more technology.
Nature - 21 September 2017.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.